Essais des produits chimiques

Lists of projects on the AOP development programme workplan

 

 

 

SECTION 1: Development of an adverse outcome pathway

Project 1.1: The Adverse Outcome Pathways for Skin Sensitisation Initiated by Covalent Binding to Proteins

Lead:

Inclusion in work plan:

Secretariat + consultant

2011

Project 1.2: The Adverse Outcome Pathways for Nonpolar Narcosis

Lead:

Inclusion in work plan:

United States

2012

 

Project 1.3: The Adverse Outcome Pathways for Acetylcholinesterase Inhibition

Lead:

Inclusion in work plan:

United States

2012

 

Draft AOP ready September 2013.

Project 1.4: Adverse Outcome Pathways for Five Cell Signalling Pathways Associated with Cell Proliferation and Differentiation that are Conserved Across Species

Lead:

Inclusion in work plan:

Secretariat + consultant

2010

 

Project 1.5: Two Adverse Outcome Pathways for Mitochondrial Toxicity

Lead:

Inclusion in work plan:

Secretariat + consultant

2011

 

Project 1.6: The Adverse Outcome Pathways for Embryonic Vascular Disruption and Developmental Defects

Lead:

Inclusion in work plan:

United States

2013

 

In progress, important milestones in 2013-2014.

Project 1.7: The Adverse Outcome Pathways for Sustained Activation of the Avian Aryl Hydrocarbon Receptor

Lead:

Inclusion in work plan:

Canada, BIAC

2013

 

Project 1.8: The Adverse Outcome Pathways for Mutagenic Modes of Action for Cancer

Lead:

Inclusion in work plan:

United States, BIAC

2014 (following re-submission)

 

Project 1.9: The Adverse Outcome Pathway on Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals

Lead:

Inclusion in work plan:

United States

2013

 

Draft AOP ready October 2013.

Project 1.10: The Adverse Outcome Pathway on Xenobiotic Induced Inhibition of Thyroperoxidase and Depressed Thyroid Hormone Synthesis and Subsequent Adverse Neurodevelopmental Outcomes in Mammals

Lead:

Inclusion in work plan:

United States

2013

 

Draft AOP ready October 2013.

Project 1.11: The Adverse Outcome Pathways for Heritable Germ Cell-Derived Disease (3 AOPs)

Lead:

Inclusion in work plan:

Canada

2013

 

AOP 1: Alkylation of DNA in male pre-meiotic germ cells causing inherited mutation; draft AOP ready in July 2013.

AOP 2: Chemical interaction with tubulin in oocytes leading to inherited aneuploidy; draft AOP ready in September 2013.

AOP 3: Stable bulky DNA adducts in male pre-meiotic germ cells causing point mutation leading to inherited DNA sequence mutation; draft AOP ready in January 2014.

Project 1.12: The Adverse Outcome Pathways linking Aromatase Inhibition, Androgen Receptor Agonism, Estrogen Receptor Antagonism, or Steroidogenesis Inhibition, to Impaired Reproduction in Small Repeat-Spawning Fish Species

Lead:

Inclusion in work plan:

United States

2013

 

Draft AOP submitted to OECD in April 2013.

Project 1.13: The Adverse Outcome Pathway on Neurotoxicant-induced Neuroinflammation: A Converging Key Event in an Adverse Outcome Pathway

Lead:

Inclusion in work plan:

Switzerland

Pending review by EAGMST

 

Project 1.14: The Adverse Outcome Pathways from Protein Alkylation to Liver Fibrosis

Lead:

Inclusion in work plan:

 

European Commission

2013

 

In progress, identification of partners.

Project 1.15: The Adverse Outcome Pathways for Neurotoxicity Induced by GABAA Receptor Inhibition

Lead:

Inclusion in work plan:

United States

2013

 

Draft AOP ready in September 2013.

Project 1.16: The Adverse Outcome Pathway Describing Hematotoxicity due to Nitroaromatics and N-hydroxyl anilines

Lead:

Inclusion in work plan:

United States

2013

 

Draft AOP ready in September 2013.

Project 1.17: The Adverse Outcome Pathway on CAR and PPARα-mediated Pathways to Non-genotoxic Rodent Liver Cancer

Lead:

Inclusion in work plan:

United States

2013

 

Draft AOP ready in February-April 2014.

Project 1.18: The Adverse Outcome Pathway on CAR and PXR-mediated Pathways to Rodent Liver Hyperplasia

Lead:

Inclusion in work plan:

United States

2013

 

Draft AOP ready in March 2014.

Project 1.19: The Adverse Outcome Pathway from Bile Salt Export Pump Inhibition to Cholestatic Liver Injury

Lead:

Inclusion in work plan:

Belgium

2013

 

Project 1.20: The Adverse Outcome Pathway for Sensitisation of the Respiratory Tract Induced by Covalent Binding to Proteins

Lead:

Inclusion in work plan:

ICAPO

2013

 

Project 1.21: Three Adverse Outcome Pathways from Peroxisome Proliferator-activated Receptors (PPARs) Activation Leading to Reproductive Toxicity in Rodents

Lead:

Inclusion in work plan:

European Commission

2014

 

Project 1.22: The Adverse Outcome Pathway from Binding of Antagonists to NMDAR during Brain Development (Synaptogenesis) Induces Impairment of Learning and Memory Abilities

Lead:

Inclusion in work plan:

European Commission

2014

Project 1.23: The Adverse Outcome Pathway from Binding of Agonists to NMDAR in Adult Brain Causes Excitotoxicity that Mediates Neuronal Cell Death, Contributing to Reduction of Cognitive Functions

Lead:

Inclusion in work plan:

European Commission

2014

Project 1.24: The Adverse Outcome Pathway from Cyp2E1 Stabilization by Substrate Binding Leading to Liver Cancer

Lead:

Inclusion in work plan:

Canada

2014

Project 1.25: The Adverse Outcome Pathway from Induction of Secretion of Inflammatory Cytokines Leading to Lung Emphysema

Lead:

Inclusion in work plan:

Canada

2014

 

SECTION 2: Development of an adverse outcome pathway case study

Project 2.1: The Adverse Outcome Pathways- Case Studies Using Aquatic Organism

Lead:

Inclusion in work plan:

United Kingdom and Japan

2013

 

Project 2.2: The Adverse Outcome Pathway on Hepatotoxicity due to 2,4,6-trinitrotoluene

Lead:

Inclusion in work plan:

United States

2013

 

Draft AOP ready in September 2013.

Project 2.3: The Adverse Outcome Pathway on Energy Metabolism by 2,6-Dinitroluene

Lead:

Inclusion in work plan:

United States

2013

 

Draft AOP ready in September 2013.

Project 2.4: The Adverse Outcome Pathway for Adipogenic Phenotype Mediated via Activation of PPARy

Lead:

Inclusion in work plan:

United States

2014

 

Project 2.5: Percellome Toxicogenomics Approach for AOP Binding: Case Study on Pentachlorophenol

Lead:

Inclusion in work plan:

Japan

2014

 

Project 2.6: Immunosuppression Initiated by Metal

Lead:

Inclusion in work plan:

Japan

2014

 

Project 2.7: A Non-mutagenic AOP for Nasal Tumours from Exposure to Weakly Genotoxic, Endogenous and Low Molecular Weight Substances: Vinyl Acetate, Acetaldehyde and Propylene Oxide

Lead:

Inclusion in work plan:

BIAC

2014

 

SECTION 3: Guidance documents related to adverse outcome pathway development including its evaluation

Project 3.1: Development of a Template for Recording Adverse Outcome Pathways (AOPs) and Associated Guidance Relating to How to Assess its Completeness

Lead:

Inclusion in work plan:

 

Secretariat

2011

 

Completed: Guidance and template published (No. 184 in OECD Series on Testing and Assessment)

Project 3.2: Glossary of the Terminology Associated with Adverse Outcome Pathways

Lead:

Inclusion in work plan:

Secretariat

2011

 

 

SECTION 4:  Knowledge management tool

Project 4.1: Web Based AOP Knowledge Management Tool

Lead:

Inclusion in work plan:

United States

2013

In development and beta-testing in 2013.

Project 4.2: Adverse Outcome Pathways Knowledge Base (AOP-KB)

Lead:

Inclusion in work plan:

European Commission, United States

2013

 

In progress.

 

SECTION 5: Others

Project 5.1: In vitro test method development strategy for the OECD Skin Sensitisation AOP

Lead:

Inclusion in work plan:

EC/ECVAM

2013

 

 

 

Also Available

Countries list

  • Afghanistan
  • Afrique du Sud
  • Albanie
  • Algérie
  • Allemagne
  • Andorre
  • Angola
  • Anguilla
  • Antigua-et-Barbuda
  • Antilles Néerlandaises
  • Arabie Saoudite
  • Argentine
  • Arménie
  • Aruba
  • Australie
  • Autorité Nationale Palestinienne
  • Autriche
  • Azerbaïdjan
  • Bahamas
  • Bahreïn
  • Bangladesh
  • Barbade
  • Belgique
  • Belize
  • Bermudes
  • Bhoutan
  • Bolivie
  • Bosnie-Herzégovine
  • Botswana
  • Brunéi Darussalam
  • Brésil
  • Bulgarie
  • Burkina Faso
  • Burundi
  • Bélarus
  • Bénin
  • Cambodge
  • Cameroun
  • Canada
  • Cap-Vert
  • Caïmanes, Îles
  • Centrafricaine, République
  • Chili
  • Chine (République populaire de)
  • Chypre
  • Colombie
  • Comores
  • Congo, La République Démocratique du
  • Corée
  • Corée, République Populaire Démocratique de
  • Costa Rica
  • Croatie
  • Cuba
  • Côte D'ivoire
  • Danemark
  • Djibouti
  • Dominicaine, République
  • Dominique
  • Egypte
  • El Salvador
  • Emirats Arabes Unis
  • Equateur
  • Erythrée
  • Espagne
  • Estonie
  • Etats Fédérés de Micronésie
  • Etats-Unis
  • Ethiopie
  • ex-République yougouslave de Macédoine (ERYM)
  • Fidji
  • Finlande
  • France
  • Gabon
  • Gambie
  • Ghana
  • Gibraltar
  • Grenade
  • Groenland
  • Grèce
  • Guatemala
  • Guernesey
  • Guinée Équatoriale
  • Guinée-Bissau
  • Guinéee
  • Guyana
  • Guyane Française
  • Géorgie
  • Haïti
  • Honduras
  • Hong Kong, Chine
  • Hongrie
  • Ile de Man
  • Ile Maurice
  • Iles Cook
  • Iles Féroé
  • Iles Marshall
  • Iles Vierges Britanniques
  • Iles Vierges des États-Unis
  • Inde
  • Indonésie
  • Iraq
  • Irlande
  • Islande
  • Israël
  • Italie
  • Jamaïque
  • Japon
  • Jersey
  • Jordanie
  • Kazakstan
  • Kenya
  • Kirghizistan
  • Kiribati
  • Koweït
  • l'Union européenne
  • Lao, République Démocratique Populaire
  • le Taipei chinois
  • Lesotho
  • Lettonie
  • Liban
  • Libye
  • Libéria
  • Liechtenstein
  • Lituanie
  • Luxembourg
  • Macao
  • Madagascar
  • Malaisie
  • Malawi
  • Maldives
  • Mali
  • Malte
  • Maroc
  • Mauritanie
  • Mayotte
  • Mexique
  • Moldova
  • Monaco
  • Mongolie
  • Montserrat
  • Monténégro
  • Mozambique
  • Myanmar
  • Namibie
  • Nauru
  • Nicaragua
  • Niger
  • Nigéria
  • Nioué
  • Norvège
  • Nouvelle-Zélande
  • Népal
  • Oman
  • Ouganda
  • Ouzbékistan
  • Pakistan
  • Palaos
  • Panama
  • Papouasie-Nouvelle-Guinée
  • Paraguay
  • Pays-Bas
  • Philippines
  • Pologne
  • Porto Rico
  • Portugal
  • Pérou
  • Qatar
  • Roumanie
  • Royaume-Uni
  • Russie, Fédération de
  • Rwanda
  • République du Congo
  • République Islamique d' Iran
  • République Tchèque
  • Sahara Occidental
  • Saint-Kitts-et-Nevis
  • Saint-Marin
  • Saint-Vincent-et-les Grenadines
  • Sainte-Hélène
  • Sainte-Lucie
  • Salomon, Îles
  • Samoa
  • Sao Tomé-et-Principe
  • Serbie
  • Serbie et Monténégro (avant juin 2006)
  • Seychelles
  • Sierra Leone
  • Singapour
  • Slovaquie
  • Slovénie
  • Somalie
  • Soudan
  • Soudan du Sud
  • Sri Lanka
  • Suisse
  • Suriname
  • Suède
  • Swaziland
  • Syrienne, République Arabe
  • Sénégal
  • Tadjikistan
  • Tanzanie
  • Tchad
  • Thaïlande
  • Timor-Leste (Timor Oriental)
  • Togo
  • Tokelau
  • Tonga
  • Trinité-et-Tobago
  • Tunisie
  • Turkménistan
  • Turks et Caïques, Îles
  • Turquie
  • Tuvalu
  • Ukraine
  • Uruguay
  • Vanuatu
  • Venezuela
  • Viêt Nam
  • Wallis et Futuna
  • Yémen
  • Zambie
  • Zimbabwe
  • Topics list